The "Most Hated CEO" in America Custom Case Solution & Analysis

Case Evidence Brief

Financial Metrics

• Acquisition Cost: Turing Pharmaceuticals purchased the rights to Daraprim from Impax Laboratories for 55 million dollars in August 2015.
• Price Appreciation: The price per tablet was increased from 13.50 dollars to 750 dollars immediately following the acquisition, representing a 5455 percent increase.
• Production Costs: Historical data suggests the manufacturing cost per tablet is approximately 1 dollar, though Turing claims high overhead and research requirements.
• Revenue Concentration: Daraprim serves as a primary revenue driver for the startup, which lacks a diversified portfolio of approved drugs.
• Research and Development Allocation: Turing stated intentions to spend 60 percent of revenue on research and development for better treatments, though specific budgets remain unverified.

Operational Facts

• Product Profile: Daraprim (pyrimethamine) is a 62-year-old medication used to treat toxoplasmosis, a parasitic infection dangerous to patients with compromised immune systems.
• Market Structure: The drug is an off-patent orphan drug with no current generic competitors in the United States market.
• Distribution Model: Turing shifted Daraprim from retail pharmacies to a controlled distribution system, making it harder for generic manufacturers to obtain samples for bioequivalence testing.
• Company Age: Turing Pharmaceuticals was founded in early 2015 by Martin Shkreli after his departure from Retrophin.

Stakeholder Positions

• Martin Shkreli (CEO): Asserts that the price increase is a rational business decision to fund future innovation and that the drug was previously undervalued.
• Medical Associations: The Infectious Diseases Society of America and the HIV Medicine Association sent joint letters calling the price increase unjustifiable and dangerous for patient care.
• Hillary Clinton and US Politicians: Publicly condemned the pricing as price gouging, leading to a 15 percent drop in the Nasdaq Biotechnology Index following a single social media post.
• Patients: Report significant barriers to access, with some hospital systems unable to stock the drug due to carrying costs.

Information Gaps

• Actual R and D Spend: The case lacks audited data confirming that 60 percent of revenue is actually directed toward toxoplasmosis research.
• Generic Entry Timeline: There is no specific data on how long it would take a competitor to gain FDA approval for a generic version under current regulatory conditions.
• Insurance Reimbursement Rates: The gap between the 750 dollar list price and the actual net price paid by insurers is not fully disclosed.

Strategic Analysis

Core Strategic Question

• How can Turing Pharmaceuticals maintain its business model of acquiring off-patent drugs while mitigating the existential threat posed by political intervention and total reputational collapse?

Structural Analysis

The pharmaceutical landscape is currently defined by high barriers to entry but extreme social and political sensitivity. Using a PESTEL lens, the following factors are critical:

• Political: The pricing strategy has triggered bipartisan Congressional scrutiny. This creates a risk of new legislation that could cap price increases or shorten exclusivity periods.
• Social: The public perceives the 5000 percent increase as a violation of the implicit social contract between healthcare providers and society. This animosity limits the ability to recruit talent or form partnerships.
• Legal: Controlled distribution strategies intended to block generics may invite antitrust investigations by the Federal Trade Commission.

Strategic Options

Option 1: Price Reversal and Volume Strategy. Reduce the price to a level that covers costs and a reasonable margin (e.g., 50 to 100 dollars per pill). This would likely end the Congressional investigation and repair relationships with hospitals.

• Trade-offs: Significant reduction in immediate cash flow; may jeopardize the 55 million dollar acquisition payback period.
• Resource Requirements: Minimal capital; requires a major shift in investor expectations.

Option 2: Tiered Pricing and Patient Assistance Programs. Maintain the 750 dollar list price for private insurers but provide deep discounts (90 percent or more) to hospitals and low-income patients through a transparent assistance program.

• Trade-offs: High administrative complexity; does not fully resolve the negative public narrative regarding the list price.
• Resource Requirements: Dedicated compliance and patient-outreach teams.

Option 3: Divestiture and Exit. Sell the rights to Daraprim to a larger, more established pharmaceutical firm with a better reputation and exit the toxoplasmosis market entirely.

• Trade-offs: Likely to sell at a loss given the current controversy; leaves the company without a flagship product.
• Resource Requirements: Investment banking services to facilitate a distressed asset sale.

Preliminary Recommendation

Turing must adopt Option 2 immediately. The company cannot survive a full price reversal without defaulting on its obligations, but it cannot survive the current political firestorm without providing a safety valve for the most vulnerable patients. This path preserves the revenue base from commercial insurers while neutralizing the most damaging stories of patient harm.

Implementation Roadmap

Critical Path

The strategy must pivot from defense to concession within a 30-day window to prevent legislative retaliation.

• Day 1-10: Establish a Patient Access Program that guarantees no patient is denied the drug due to cost. Automate the approval process to ensure zero delay in treatment.
• Day 11-20: Direct negotiation with major hospital buying groups to offer bulk-purchase discounts that bring the effective cost back to historical norms for inpatient care.
• Day 21-30: Appoint a Chief Medical Officer with high credibility in the infectious disease community to oversee all pricing and R and D decisions.

Key Constraints

• CEO Public Persona: The combativeness of Martin Shkreli on social media undermines all formal corporate communications. Success depends on his withdrawal from public discourse.
• Regulatory Scrutiny: The FDA or FTC may fast-track generic competitors regardless of Turing's actions, shortening the window to recoup the 55 million dollar investment.

Risk-Adjusted Implementation Strategy

The primary risk is that concessions are viewed as too little, too late. To mitigate this, Turing should commit to an audited R and D roadmap. By tying the high price of Daraprim to specific, time-bound milestones for a next-generation treatment, the company shifts the argument from greed to innovation. If milestones are missed, the company should pre-commit to automatic price reductions.

Executive Review and BLUF

BLUF

Turing Pharmaceuticals faces an existential crisis driven by a failure to account for political and social externalities in its pricing model. The current 750 dollar price point is unsustainable. To prevent a total loss of the 55 million dollar investment through government intervention or forced generic entry, Turing must immediately implement a tiered pricing structure. This move protects commercial revenue while ensuring hospital and patient access. The CEO must be removed from the public face of the company to allow for a credibility reset. Failure to act within the next quarter will likely result in a permanent loss of the asset's value.

Dangerous Assumption

The most dangerous assumption is that the lack of generic competition provides a permanent monopoly. In a high-outcry environment, the FDA can exercise discretionary power to accelerate alternative approvals, and hospitals can turn to compounding pharmacies to bypass the manufacturer entirely.

Unaddressed Risks

• Compounding Pharmacy Substitution: There is a high probability that major hospital chains will begin sourcing pyremethamine from compounding pharmacies at a fraction of the cost, rendering the 750 dollar price irrelevant.
• Capital Market Access: The reputational damage may prevent Turing from raising the future rounds of capital necessary to actually fund the research and development it uses to justify its pricing.

Unconsidered Alternative

The team failed to consider a non-profit partnership model. Turing could license the manufacturing rights for Daraprim to a non-profit entity for use in the public sector while retaining private insurance rights. This would effectively bifurcate the market and remove the ethical stain of profiting from the uninsured or underinsured.

VERDICT: APPROVED FOR LEADERSHIP REVIEW